Medicines for Malaria Venture (MMV) recently announced that the Australian Therapeutic Goods Administration (TGA) had approved the use of single-dose Kozenis (tafenoquine) in children in combination with chloroquine for the prevention of relapse of Plasmodium vivax (P. vivax) malaria.
The TGA approval confirmed on March 14, 2022, includes a novel, 50 mg dispersible tablet that can be dispersed in water and developed by GSK in partnership with MMV to facilitate use in children who are disproportionately affected by the disease.
Single-Dose Malaria Relapse Pill Approved in Australia
2016 to 2020 Saw Anxiety, Depression Increase Among Children
From 2019 to 2020, increases seen in behavior or conduct problems and decreases seen in preventive medical visits
Prevalence of Depression Up Among Those Diagnosed With COVID-19
Prevalence of symptoms of depression and anxiety increased among those with COVID-19 who were bedridden for more than seven days
Rise in U.K. COVID-19 Cases Closely Watched by U.S. Health Officials
U.K. saw a 48 percent increase in COVID-19 cases and a 17 percent rise in hospitalizations last week